From: Stock Gumshoe<travis@stockgumshoe.com>
Subject: Doc Gumshoe's March 2018 "Catch up"
Preheader: Which drugs catch the eye from last year?
Reply: travis@stockgumshoe.com
You're receiving this email newsletter because you, or someone
using newsletter@newslettercollector.com, signed up for the Stock Gumshoe Daily Update
 
Please unsubscribe if you don't want Stock Gumshoe emails
(this will not cancel membership, just stop emails). 

DAILY UPDATE
March 14, 2018
email formatted funny? Web version
Dear Valued Reader,

I just spent a bit of time banging my head against an article that refused to get written, so I'm quite grateful that Michael Jorrin just popped in with his latest "Doc Gumshoe" piece... so despite my failure to produce today, we've got something interesting and new for you to read.  Michael's doing his "March 2018" check up, including a look at what the FDA approvals looked like last year in comparison to the past, and which of those drugs look like "winners."  Just click below for that piece...


Investing in this small group of stocks is the most reliable way to make big money from the markets in 2018. Just 30 stocks have generated $300 million in windfall profits every day for the last 90 years. Get the full story in this free video briefing. Watch it now.


Advertisement

Have you seen the ads from the Motley Fool talking up the "Ticking Time Bomb" that's being faced by cable TV?  They've got a stock they think will benefit, which is one of their "Total Conviction" recommendations and, they say, looks like a pre-IPO Facebook.  That enough hype for you?  Wait, there's more!  We've got a lovely little Thinkolator answer to the riddle for you, just click below to...


Disclaimer: Nothing in this email or in the linked articles should be considered to be individual investment advice -- we can't tell you what you should do with your money, we can just share our opinions and perspective. Our authors try to use reliable information sources but also make mistakes of both fact and judgement on occasion, so all assertions should be checked and confirmed. You should speak with your financial advisor and understand everything fully before committing money to any investment.

Most issues of this email newsletter include advertising, and it should not be assumed that the presence of an advertisement means that the product or service advertised is endorsed by Stock Gumshoe or the author. For full disclaimers, disclosure information, and privacy policies please see the prominent links at the bottom of each page at StockGumshoe.com.

If you wish to unsubscribe to these mailings, there are links at both the bottom and top of this email that you can use to do so permanently and safely, we have no wish to email people who don't want to receive these messages. Please note that unsubscribing using the link below applies only to receiving emails, if you are a member of the Stock Gumshoe Irregulars that membership will not automatically change or be canceled. Please contact us if you need to change a paid membership.
Unsubscribe
Stock Gumshoe, 351 Pleasant St., Suite B #205, Northampton, MA 01060